In Brief: Medtronic/Computer Motion
This article was originally published in The Gray Sheet
Executive Summary
Medtronic/Computer Motion: Form partnership under which Medtronic will invest an undisclosed sum to help develop the Goleta, California-based medical robotics firm's Zeus computer-assisted robotic system for minimally invasive cardiac bypass graft surgery in exchange for receiving exclusive distribution rights in Europe, the Middle East and Africa. Medtronic also will gain co-marketing rights in the U.S. and Canada for the voice- and computer-controlled system, which positions an endoscope and instruments to aid surgical manipulations...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.